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Abstract
Background
Recent GWAS studies have identified more than 300 SNPs associated with variation in
blood pressure. We investigated whether a genetic risk score constructed from these vari-
ants is associated with burden of coronary heart disease.
Methods
From 2010–2014, 4,809 individuals admitted to coronary angiography in Capital Region of
Copenhagen were genotyped. We calculated hypertension GRS comprised of GWAS iden-
tified SNPs associated with blood pressure. We performed logistic regression analyses to
estimate the risk of hypertension and prevalent CHD. We also assessed the severity of
CHD associated with the GRS. The analyses were performed using GRS quartiles. We
used the Inter99 cohort to validate our results and to investigate for possible pleiotropy for
the GRS with other CHD risk factors.
Results
In COGEN, adjusted odds ratios comparing the 2nd, 3rd and 4th cumulative GRS quartiles
with the reference were 1.12(95% CI 0.95–1.33), 1.35(95% CI 1.14–1.59) and 1.29(95% CI
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1.09–1.53) respectively, for prevalent CHD. The adjusted multinomial logistic regression
showed that 3rd and 4th GRS quartiles were associated with increased odds of developing
two(OR 1.33, 95% CI 1.04–1.71 and OR 1.36, 95% CI 1.06–1.75, respectively) and three
coronary vessel disease(OR 1.77, 95% CI 1.36–2.30 and OR 1.65, 95% CI 1.26–2.15,
respectively). Similar results for incident CHD were observed in the Inter99 cohort. The
hypertension GRS did not associate with type 2 diabetes, smoking, BMI or hyperlipidemia.
Conclusion
Hypertension GRS quartiles were associated with an increased risk of hypertension, preva-
lent CHD, and burden of coronary vessel disease in a dose-response pattern. We showed
no evidence for pleiotropy with other risk factors for CHD.
Introduction
Hypertension has been estimated to account for >45% of all coronary heart disease (CHD)
events worldwide [1]. The relation between genetic determinants of hypertension and the
development of CHD can therefore be important for understanding disease mechanisms.
More than 300 single nucleotide polymorphisms (SNPs) with relation to hypertension have
been identified in genome-wide association studies (GWAS) [2], [3]. The relation between
these many hypertension associated SNPs and occurrence of CHD has received limited atten-
tion. A single study has indicated a dose-response relationship of increased risk of CHD asso-
ciated with the number of hypertension associated SNPs [4]. There are no studies of a relation
between hypertension associated SNPs and severity of CHD. Further understanding of the
genetic architecture of hypertension and CHD requires interrogation of datasets where the
CHD phenotype is very certain and also quantifiable.
We have for the current study used a dataset from 4,809 individuals that have been sub-
jected to genotyping and coronary angiography enabling us determine the presence/absence
of CHD with very high certainty and further to quantify the extent of disease by number of
vessels affected. In this report we calculated a genetic risk score using coefficients from a prior
GWAS study and analyzed the relation between the genetic risk score and both presence and
severity of CHD.
Methods
Study populations
COGEN. The Copenhagen Cardiovascular Genetic study (COGEN) is a biobank that
includes ~80,000 individuals admitted to six cardiology departments in the Greater Region of
Copenhagen, Denmark, from 2010–2017. The present study is based on a sample of ~5,900
individuals who have had at least one coronary angiogram performed between 2010–2014 and
who have been genotyped as described below and in the online supporting information.
Information on diagnostic results from angiograms was obtained from The Eastern Danish
Heart Registry. Included in the Eastern Danish Heart Registry are clinical data on all patients
undergoing cardiac catheterization and coronary revascularization in Eastern Denmark since
1998 [5]. The registry includes information on demographics (e.g. age, gender), risk factors
and comorbidities (e.g. smoking status, diabetes, hypertension) and coronary pathology.
Patients with significant CHD were defined as patients needing percutaneous coronary
Hypertension GRS associates with burden of CHD
PLOS ONE | https://doi.org/10.1371/journal.pone.0208645 December 19, 2018 2 / 17
request to authorized scientists by contacting
Statistics Denmark: http://www.dst.dk/en/OmDS/
organisation/TelefonbogOrg.aspx?kontor=
13&tlfbogsort=sektion or the Danish Data
Protection Agency: https://www.datatilsynet.dk/
english/the-danish-data-protection-agency/contact/
. More information regarding data access is
available at https://www.dst.dk/en/TilSalg/
Forskningsservice.
Funding: The author(s) received no specific
funding for this work.
Competing interests: The authors have read the
journal’s policy and the authors of this manuscript
have the following competing interests: The Novo
Nordisk Foundation Center for Basic Metabolic
Research performed genotyping, quality control of
the genotypes and genotype imputation. The Novo
Nordisk Foundation Center for Basic Metabolic
Research is an independent Research Center at the
University of Copenhagen partially funded by an
unrestricted donation from the Novo Nordisk
Foundation (www.metabol.ku.dk). There are no
patents, products in development or marketed
products associated with this research to declare.
This does not alter our adherence to PLOS ONE
policies on sharing data and materials.
intervention (PCI) or coronary artery bypass surgery (CABG). Moreover, this registry also
provides data on the type of clinical presentation such as ST-elevation myocardial infarction
(STEMI), non-ST elevation myocardial infarction (NSTEMI), unstable (UAP) and stable
angina pectoris (SAP).
We included 4,809 patients in the present study after excluding patients with missing values
on one of the following variables: age, gender, smoking, BMI, history with acute myocardial
infarction (AMI), coronary artery bypass surgery (CABG), peripheral artery disease (PAD),
diabetes, hypertension, hyperlipidemia, stroke.
Inter99. To analyze whether the hypertension GRS is associated with CHD also in a popu-
lation based cohort (i.e. corresponding to a primary preventive setting), we used the Inter99
population, a cohort from 11 municipalities in the south-western part of Copenhagen. This
population has been described in detail previously [6]–[8]. In brief, the Inter99 study is a ran-
domized, non-pharmacological intervention study for prevention of ischemic heart disease on
more than 13,000 individuals between 30 and 60 years randomly selected from the Civil Regis-
tration System. The study was conducted at the Research Centre for Prevention and Health in
Glostrup, Denmark (https://www.regionh.dk/rcph/population-based-epidemiology/Pages/
The-Inter99-Study.aspx) [6]. Participants were further prerandomized into high-intensity
(90%) and low-intensity (10%) intervention groups. Baseline health examinations were
attended by 6,784 (52%). At baseline all individuals received individual lifestyle counseling,
with focus on smoking, use of alcohol, diet and physical activity. Participants in the high inten-
sity groups were, additionally, offered group-based lifestyle counseling if they were evaluated
at high risk for developing ischemic heart disease. Follow-up examinations after 5 years were
conducted with a participation rate of 66% (n = 4,511) [7], [9]. This intervention study was of
rather low intensity with examinations and counseling up to four times over five years. Indi-
viduals at high risk of ischemic heart disease, were offered six extra group-based lifestyle
counseling sessions. The intervention study had no effects on ischemic heart disease, stroke
and all-cause mortality after 10 years [10]. Overall, genotype information was available on
6127 individuals, but 1215 participants were excluded due to missing values on age, gender,
smoking, BMI, history with AMI, diabetes, hypertension, hyperlipidemia and stroke. Hyper-
tension was defined by the use of antihypertensive treatment or blood pressure measurements
over 140/90 mm Hg at study entry. In the present study, we used the Inter99 population to
investigate for pleiotropy between the hypertension GRS and other CHD risk factors defined
as type 2 diabetes, BMI, hyperlipidemia, and smoking.
Genotyping, imputation and quality control
In COGEN, genome-wide genotyping was performed using the Illumnia Infinium Human Cor-
eExome Beadchip-24 v1.0 (Illumnia, San Diego, CA, USA) and mapped to GRCh37.p13 assem-
bly (i.e. hg19). Genotypes were called using the Genotyping module (version 1.9.4) of
GenomeStudio Software (version 2011.1, Illumina). We removed variants with missingness
above 5%, and excluded individuals who had a call-rate below 95%, extreme inbreeding coeffi-
cients, mislabelled sex, were non-ethnical Danes (based on principal component analysis), or
duplicates. We excluded one individual in each close family pair (Siblings, monozygotic twins or
parent-offspring) pair identified by an identity by descent (IBD) analysis. In total 5,128 patients
and 539,004 variants passed quality control (QC) analyses and were eligible for imputation.
Imputation was performed on the Sanger Imputation Server using haplotypes from the
Haplotype Reference Consortium (HRC version r1.1) panel [11] on the subset of variants that
were not significant in a Hardy Weinberg Equilibrium test (p<0.0001). Supporting informa-
tion S1 File includes detailed information about genotyping, QC analyses and imputation.
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Individuals from Inter99 were genotyped using the Cardio-Metabochip [12] and Human
Exome BeadChip on an Illumina HiScan system (Illumina, San Diego, CA). Quality control
and genotype calling have previously been described [13].
Single nucleotide polymorphism selection and GRS
We identified 301 SNPs that reached genome-wide significance (p = 5×10−8) for SBP, DBP
and/or PP from the largest GWAS meta-analysis to date by Hoffmann et al [3]. Of these, 12
SNPs were excluded due to a minor allele count (MAC) < 20 in our study sample (S1 Table
for details). Overall, 33 SNPs were not captured by genotyping or subsequent imputation. Of
these we identified relevant proxy SNPs for a total of 10 SNPs (r2 > 0.8 according to LDlink
[14]), and 23 SNPs did not have relevant proxies (S2 Table).
We calculated two different scores where we oriented each coding allele to be the risk allele,
regardless of allele frequency. In the unweighted GRS (uGRS), we assigned 1 point per risk
allele assuming an additive risk model. GRSi is the unweighted GRS for individual i, sij is the
number of effect increasing alleles for the j’th SNP for individual i and N is the number of
SNPs in the GRS:
uGRSi ¼
XN
j¼1
sij
In the weighted GRS (wGRS), the risk alleles were weighted by the effect size (beta-esti-
mates) of the variant reported in the relevant discovery study [3], [15], [16]. Thus, for the
wGRS, we multiplied each allele with the reported effect size, after which we summed up the
total value of all weighted SNPs. We then normalized by dividing by the average effect size.
wGRSi is the weighted GRS for individual i, sij is the number of effect increasing alleles for the
j’th SNP for individual i, N is the number of SNPs in the GRS and βj is the reported effect size
for the j’th SNP.
wGRSi ¼
N
PN
j¼1 βj
XN
j¼1
βjsij
Both scores were afterwards standardized to have mean zero, and a standard deviation at
one.
No correlated SNPs were found applying an LD-filter (r2 <0.8). SNPs and effect sizes used
for weighting of the specific variants can be found in S3 Table.
Statistical analyses
Logistic regression analysis was used to assess the relation of prevalent hypertension and CHD
associated with the calculated uGRS. In order to analyze the impact of uGRS on burden of cor-
onary vessel disease (i.e. zero-, one-, two-, or three- coronary vessel disease) we performed
multinomial logistic regression with four strata of the dependent variable: no coronary vessel
disease, one coronary vessel disease, two coronary vessel disease and three coronary vessel dis-
ease. The multivariable model was adjusted for age, gender, smoking, BMI, diabetes, hyperlip-
idemia, stroke and peripheral artery disease (PAD). We used, in the main analyses, the uGRS
instead of the wGRS to ascertain the risk of prevalent hypertension and CHD as the weights
derived from risk factor discovery study, where the coefficients reflect relative risks and not
absolute risks that are applicable to the general population [17]. However, we also analyzed
whether the wGRS followed the same trend as the uGRS and included the results in the online
supporting information. We also evaluated the risk of coronary heart disease in relation to the
Hypertension GRS associates with burden of CHD
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each of the three hypertension traits (SBP, DBP and PP) individually. Finally, we ascertained
whether there were associations between hypertension GRS and other risk factors including
diabetes, smoking, BMI or hyperlipidemia.
The analyses were performed using u/wGRS quartiles with the lowest interval as reference.
When presenting the results, we refer to these quantiles as 1st (lowest), 2nd, 3rd and 4th (highest)
quartiles. Age was also divided into quartiles, using the youngest as reference. No interaction
between age and GRS was found regardless of the outcome (hypertension and CHD). We
divided BMI into the following subgroups: underweight (<18.5 kg/m2), normal weight (18.5–
25 kg/m2), overweight (25.1–30 kg/m2) and obese (>30 kg/m2) [18]. Patients with normal
weight were used as reference. We used the Analysis of variance (ANOVA) to test whether
there was a statistical difference in hypertension GRS in relation to number of vessel disease.
Analyses were performed R statistical software (version 3.0.1, R development core team).
Ethics
All data were de-identified prior to analyses. Written informed consent was obtained from all
participants included in the present study. The ethics committee of Region North Jutland (N-
20140048) approved the project and COGEN has permission from the Data Protection Agency
(00916 GEH-2010-001). The Inter99 study was approved by the Scientific Ethics Committee of
the Capital Region of Denmark (KA98155) and registered as clinical trial (ClinicalTrials.gov;
ID-no: NCT00289237). Both studies were performed in accordance with the principles of the
Declaration of Helsinki.
Results
Demographics (COGEN)
The characteristics of the study population undergoing coronary angiography are presented in
Table 1. Median age in the population was 66.2 years [IQR: 57.6, 73.6] and 64.2% were males.
Approximately 55% of the patients were known with hypertension. Moreover, 39.3% of the
patients were overweight and 26.5% were obese. Median wGRS and uGRS was 398.4 [IQR:
389.5, 407.5] and 383.6 [IQR: 373.9, 393.4] respectively. Supporting information S1 and S2
Figs. illustrate boxplots of hypertension GRS distribution according to prevalent hypertension
and number of affected coronary vessels, respectively. The most common causes of referral for
CAG were SAP (43%), STEMI (17%), NSTEMI (9.5%), and UAP (7.3%). Overall, 53.9% of
patients had significant CHD verified by CAG; one-coronary vessel disease comprised 26.6%,
two-coronary vessel disease 13.9% and, three-coronary vessel disease comprised 13.4%. A total
of 46.1% of patients referred for CAG did not have significant CHD.
ANOVA showed that hypertension GRS is overall statistically different throughout the four
vessel disease strata. Generalized linear models revealed no difference in hypertension GRS in
patients with one-coronary vessel disease compared to none-coronary vessel disease (S4
Table). We observed 64 SNPs that were associated with two or three of the blood pressure
traits. However, we found no correlation between SBP, DBP and PP scores.
Hypertension genetic risk score and risk of prevalent hypertension
(COGEN)
We assessed the validity of the hypertension GRS in our study population. Both unadjusted
and adjusted models showed a dose-response relationship between uGRS and the increased
odds of hypertension. Results of these analyses can be seen in S3 Fig.
Hypertension GRS associates with burden of CHD
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Table 1. Demographics (N = 4,809).
Variable Total
Age (median [iqr]) 66.2 [57.6, 73.6]
Gender (male) 3089 (64.2%)
wGRSa (median [iqr]) 398.4 [389.5, 407.5]
wGRSb (quantiles)
1.Q. 1259 (26.2%)
2.Q. 1222 (25.4%)
3.Q. 1187 (24.7%)
4.Q. 1141 (23.7%)
uGRSc (median [iqr]) 383.6 [373.9, 393.4]
uGRSd (quantiles)
1.Q. 1257 (26.1%)
2.Q. 1229 (25.6%)
3.Q. 1185 (24.6%)
4.Q 1138 (23.7%)
No. of vessel disease
0 2219 (46.1%)
1 1277 (26.6%)
2 670 (13.9%)
3 643 (13.4%)
Smoking 1153 (24.0%)
BMIe
Underweight 58 (1.2%)
Normal range 1588 (33.0%)
Overweight 1890 (39.3%)
Obese 1273 (26.5%)
Hypertension 2707 (56.3%)
Hyperlipidemia 2778 (57.8%)
Diabetes 843 (17.5%)
Stroke 382 (7.9%)
Peripheral artery disease 302 (6.3%)
Acute myocardial infarction 700 (14.6%)
CABGf 329 (6.8%)
CAGg referral diagnosis
Stable angina pectoris 2058 (43.0%)
Unstable angina pectoris 350 (7.3%)
Non-STEMI 454 (9.5%)
STEMI 831 (17.4%)
Chronic heart failure 279 (5.8%)
Other 817 (17.1%)
missing 20
awGRS- weighted genetic risk score
buGRS quantiles based on the number of hypertension increasing risk alleles: 1.Q. [337, 374]; 2.Q. (374, 384]; 3.Q.
(384, 394]; 4.Q.(394, 442]
cuGRS- unweighted genetic risk score
duGRS quantiles based on the number of hypertension increasing risk alleles: 1.Q. [353, 390]; 2.Q. [390, 399]; 3.Q.
[399, 408]; 4.Q. [408, 453]
eBMI- body mass index
fCABG- coronary artery bypass graft
gCAG- coronary angiography
https://doi.org/10.1371/journal.pone.0208645.t001
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Hypertension genetic risk score and risk of significant coronary heart
disease (COGEN)
The adjusted model with significant CHD entered as the outcome variable showed that 3rd and
4th quartiles of the uGRS were associated with increased odds of CHD (OR 1.35, 95% CI 1.14–
1.59 and OR 1.29 95% CI 1.09–1.53 respectively, Fig 1) among patients referred for CAG com-
pared to individuals in the 1st quartile. The univariable analysis showed similar results (Fig 1).
We observed similar results using wGRS (S4 Fig).
Hypertension genetic risk score and burden of significant coronary heart
disease (COGEN)
Among patients referred for CAG, no association between uGRS quartiles and one vessel coro-
nary heart disease was identified neither in the unadjusted or the adjusted models (as com-
pared with no significant obstructive vessel disease, Fig 2).
Among patients with two coronary vessel disease the multivariable analysis showed an asso-
ciation between 3rd and 4th uGRS quartiles and increased odds of significant coronary vessel
disease with odds ratios OR 1.33 and 1.36 (95% CI 1.04–1.71, p = 0.03 and 95% CI 1.06–1.75,
p = 0.02 respectively, Fig 2).
Among patients with three coronary vessel disease, both the unadjusted and adjusted analy-
ses showed that patients in 2nd, 3rd and 4th uGRS quartiles had increased odds of significant
coronary disease when compared to patients in 1st quartile (OR 1.32, 95% CI 1.01–1.72; OR
1.77 95% CI 1.36–2.30 and OR 1.65 95% CI 1.26–2.15 respectively, Fig 2).
Similar results were observed using wGRS (S5 Fig).
Population based analyses (Inter99)
Risk of prevalent MI associated with hypertension GRS was evaluated in a population based
setting using the Inter99 cohort. Baseline demographics are shown in S5 Table. Here we found
that 4th quartile of hypertension associated GRS was significantly associated with increased
risk of developing myocardial infarction in unadjusted and adjusted models with 1.98 and 2.02
fold increased risk of MI respectively (95% CI 1.08–3.64 and 1.09–3.75) (S6 Fig).
We also evaluated the pleiotropy of hypertension uGRS with diabetes, smoking, BMI and
hyperlipidemia. Our results showed no evidence for pleiotropy between hypertension uGRS
and the above mentioned CHD risk factors (S6 Table).
Sensitivity analyses (COGEN and Inter99)
We performed three sensitivity analyses. First, we evaluated whether hypertension GRS was
associated with CHD and burden of disease in individuals not diagnosed with hypertension in
both COGEN and Inter99 populations. In COGEN, we generally observed the same effect
sizes as in the main analysis, however the association of 3rd uGRS quantile with 2-coronary
vessel disease did not remain significant (p = 0.10, Fig 3).
In Inter99, we observed higher ORs and larger CIs (Fig 4) compared to the main analysis.
Furthermore, 2nd uGRS quantile was statistically significant in this stratified analysis both in
the unadjusted and adjusted model (OR 5.18; 95% CI 1.50–17.97; p<0.01 and OR 6.12; 95%
CI 1.73–21.63; p<0.01, Fig 4). The same observation was made regarding 3rd uGRS quantile
(OR 3.56; 95% CI 0.98–12.98; p = 0.05 and OR 4.20; 95% CI 1.13–15.60; p = 0.03, Fig 4).
Second, we ascertained to which extent each of the three blood pressure traits, namely SBP,
DBP and PP, contributed to the risk of CHD in COGEN population. The adjusted model with
significant CHD entered as the outcome variable showed that 4th unweighted systolic blood
Hypertension GRS associates with burden of CHD
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pressure (uSBP) GRS quantile was associated with increased CHD risk (S7 Fig). Unweighted
pulse pressure (uPP) GRS’ 2nd, 3rd and 4th quartiles were significantly associated with increased
odds of CHD (S9 Fig). No association with increased odds of CHD was observed in relation to
unweighted diastolic blood pressure (uDBP) GRS (S8 Fig).
Third, we performed multinomial logistic regression analysis where individuals with previ-
ous history of acute myocardial infarction (AMI) were excluded. The reason was to verify
whether these individuals carry a higher risk of developing CHD. We observed no differences
in estimates compared to the main analysis (S10 Fig).
Discussion
This hypertension GRS study involving 4,809 patients who were admitted to a coronary angi-
ography (COGEN) and a population based cohort (Inter99) had six essential findings. First,
Fig 1. Association of blood pressure uGRS with CHD (binary outcome) in COGEN cohort (N = 4,809).
https://doi.org/10.1371/journal.pone.0208645.g001
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we observed an association between higher hypertension GRS with greater risk of coronary
heart disease. Second, our study demonstrated a dose-response pattern between the hyperten-
sion GRS and the severity of coronary heart disease among patients referred to coronary angi-
ography. Third, the study demonstrated that, a hypertension GRS was independently
associated with increased odds of developing CHD in a population based setting. Fourth, the
association of hypertension GRS with increased odds of CHD was regardless of being diag-
nosed with hypertension or receiving antihypertensive treatment. Fifth, PP and SBP suscepti-
bility GRS were the strongest predictors of coronary artery disease development. Sixth, there
was no evidence of pleiotropy between hypertension GRS and diabetes, smoking, BMI or
hyperlipidemia.
Our findings add to the notion of hypertension being strongly associated with risk of devel-
oping CHD. However, we were also able to demonstrate that patients with a stronger genetic
Fig 2. Association of blood pressure uGRS with CHD (multilevel outcome) in COGEN cohort. (N = 4,809).
https://doi.org/10.1371/journal.pone.0208645.g002
Hypertension GRS associates with burden of CHD
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predisposition to develop hypertension (based on known hypertension SNPs) suffered from
more severe coronary heart disease compared to those with less genetic burden to develop
hypertension. These findings are of particular interest, given that the SNPs included in the
present study account for only ~2% of the overall heritability of hypertension and are corre-
lated with risk of CHD development, but also the degree of disease [19]. Thus, with a better
understanding and identification the genetic architecture predisposing patients to develop
Fig 3. Association of blood pressure uGRS with CHD in individuals with no pre-hypertension (COGEN)
(N = 2,707).
https://doi.org/10.1371/journal.pone.0208645.g003
Hypertension GRS associates with burden of CHD
PLOS ONE | https://doi.org/10.1371/journal.pone.0208645 December 19, 2018 10 / 17
hypertension, more of the disease variability can be accounted for, which translates into an
improved risk prediction of CHD development and severity. Yet, the association of different
SNPs with increased risk of hypertension does not give any insight into the mechanism of
development of hypertension. SNPs can affect molecular function and contribute to disease
Fig 4. Association of blood pressure uGRS with AMI in individuals with no pre-hypertension (Inter99)
(N = 3,742).
https://doi.org/10.1371/journal.pone.0208645.g004
Hypertension GRS associates with burden of CHD
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risk through different mechanisms such as altered transportations rate of a protein, altered
protein folding or message processing and message stability. We also showed that individuals
had an increased risk of hypertension regardless of being diagnosed and/or treated for hyper-
tension. An argument for this finding can be great arterial stiffness in the non-hypertensive
individuals which represents an early stage in the pathogenesis of hypertension. In 1,564 non-
hypertensive Framingham Heart Study third-generation cohort participants, Andersson et al.
[20] showed that non-hypertensive adults had higher vascular stiffness if they were offspring of
one or two parents with hypertension compared to those with no familial predisposition.
Unfortunately, due to great missingness of self-reported information on familial hypertension
we could not account for this major confounder.
Generally, our findings are in agreement with other recent studies. Hoffmann et al. [3]
investigated the association of SBP, DBP and PP susceptibility GRSs with MI/CHD and the
authors found that a GRS constructed from 70 SNPs were highly significantly associated with
MI/CHD with odds of 1.06 (p = 1.1 x 10−45) per 1 mmHg increase in SNP-based BP. Likewise,
Surendran et. al. [19] found that blood pressure traits such as SBP, DBP and PP were positively
associated with increased CHD risk. The results of our study are not suggestive of an associa-
tion between DBP susceptibility GRS and increased odds of CHD neither as binary nor as mul-
tilevel outcome. Frankling et al [21] showed in 6,539 Framingham Heart Study participants,
who were not on antihypertensive therapy at baseline, that there was a gradual shift from DBP
to SBP and then to PP as predictors of CHD risk with increasing age. The same was concluded
by Franklin et al. in 2013 [22] when discussing the most important contributions of the Fra-
mingham Heart Study on epidemiology of blood pressure. Our study included approximately
20% individuals under the age of 50 years, which could explain the lack of association between
the DBP susceptibility GRS and increased CHD risk. Another study looked at the impact of
cumulative hypertension GRS on coronary heart disease [4]. The study showed that the GRS
was associated with increased risk of CHD when comparing upper and lower quintiles of the
GRS (OR 1.38, p = 4.3×10−23). This is consistent with our findings, where we found 32% and
27% higher odds of prevalent CHD among patients in the 3rd and 4th quartiles compared to
those in the lowest quartile.
To our knowledge, the present study is the first to demonstrate a dose-response pattern
associated with the genetic burden of hypertension associated SNPs and severity of CHD.
Notably, we found an association of 3rd and 4th uGRS quantiles with increased odds of devel-
oping two- and three coronary vessel disease in patients referred to angiography compared to
1st uGRS quartile.
Coronary heart disease risk prediction has a central role in daily clinical practice and strong
efforts are made to improve risk assessment methodology, as traditional risk factors do not
identify most individuals with high CHD risk. Recently, increased attention has been directed
towards the identification of genetic risk markers and quantification of the improvement in
risk prediction models that include GRS in general [23]. As far as our knowledge, only one
study, directly investigated the effect of inclusion of hypertension GRS in a cardiovascular risk
stratification score system. The authors found that inclusion of hypertension GRS of the aggre-
gated risk effects of the associated loci into a cardiovascular risk prediction model could
improve both patient risk classification and blood pressure regulation [24]. Several studies
found positive association between GRS awareness on “soft” end points (e.g. information seek-
ing on the disease) but only few succeeded to find associations in “hard” endpoints (e.g. mor-
tality). For example, one study showed that individuals which were aware of their personal
CHD risk based on CHD susceptibility GRS seemed to show an increased tendency to seek
and share disease related information [25]. Khera et al. [26] investigated to which extent
increased CHD genetic risk can be offset by a healthy lifestyle. The authors found that
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individuals in the top quintile of the CHD susceptibility GRS had a substantially lower risk of
coronary events if they adhered to a favorable lifestyle [26].
As we observed, information on the effect of including GRSs in cardiovascular risk predic-
tion score systems are sparse, especially when referring to hypertension GRS. However, the
available studies suggest that awareness of genetic susceptibility improves regulation of some
of the risk factors included in the traditional prediction models (e.g. hypertension and life-
style). Future studies investigating whether awareness of hypertension GRS decreases blood
pressure and increases patient compliance to antihypertensive therapy are needed. Moreover,
studies investigating performance of CHD risk prediction models when hypertension GRS is
included are warranted in order to identify as many patients at risk as possible. Furthermore, a
more sensitive and specific cardiovascular risk prediction score system could be beneficial
especially when referring to individuals with increased risk of CHD involving multiple coro-
nary vessels as this patient group has increased risk of developing MI induced comorbidity
such as heart failure or kidney disease [27], [28].
Study strengths and limitations
This study’s major strength is represented by inclusion of a rather large and clinically represen-
tative cohort of individuals referred to coronary angiography—including information in the
extent of CHD.
The limitations are largely related to the observational nature of the study. Furthermore,
our population is highly selected, as its main inclusion criteria is admission to coronary angi-
ography, mainly due to symptoms or clinical presentation where CHD is suspected. However,
by including a population based cohort (Inter99) which yielded similar findings in terms of a
significant association between hypertension GRS and MI adds to the external validity of the
study. Yet, the results using data of the Inter99 study might be underestimated due to the low
follow-up rate (66%).
Our population may not extend to other non-Europeans Caucasian populations, which can
lead to difficulty in reproducing these results worldwide.
Perspectives
A hypertension GRS comprised of a large number of GWAS identified SNPs was associated
with increased burden of CHD. This finding is an important step in building and evaluating
absolute risk models for the general population. Early and accurate identification of individu-
als at risk might implicitly lead to more effective implementation of preventative lifestyle mod-
ifications, improve treatment compliance and intensive follow-up.
Conclusion
In the present study, we identified a significant dose-response pattern between a GRS on
GWAS identified common genetic variants associated with systolic blood pressure, diastolic
blood pressure, or pulse pressure and the risk of hypertension, CHD and also degree of coro-
nary vessel disease such as multi vessel disease in individuals who were admitted to a coronary
angiography. The association of hypertension GRS with increased odds of CHD was indepen-
dent of individuals being diagnosed or receiving treatment for hypertension. PP and SBP GRS
seemed to be the strongest determinants of CHD when compared with DBP GRS. We showed
no evidence for pleiotropy between hypertension GRS and diabetes, smoking, BMI or hyper-
lipidemia in a population-based sample. Whether the inclusion of hypertension GRS in
known CHD risk models will improve survival remains to be determined.
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